quantisnow
FeedTopReportsPricing
⌘K
Live feed
14:33:00·836d
NEWSRelease
Ambrx Biopharma Inc. logo
Commercial Metals Company logo
Dada Nexus Limited logo
+4

Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results

AMAM· Ambrx Biopharma Inc.CMC· Commercial Metals CompanyDADA· Dada Nexus LimitedDTC· Solo Brands Inc.HARP· Harpoon Therapeutics Inc.LMDX· LumiraDx Limited
Health CareIndustrialsTechnology
Original source

Companies

  • AMAM
    Ambrx Biopharma Inc.
    Health Care
  • CMC
    Commercial Metals Company
    Industrials
  • DADA
    Dada Nexus Limited
    Technology
  • DTC
    Solo Brands Inc.
    Consumer Discretionary
  • HARP
    Harpoon Therapeutics Inc.
    Health Care
  • LMDX
    LumiraDx Limited
    Health Care
  • NKTX
    Nkarta Inc.
    Health Care

Recent analyst ratings

  • Apr 1CMCUpdateGoldman$74.00
  • Mar 25CMCUpdateKeyBanc Capital Markets-
  • Dec 10CMCUpdateJefferies$78.00
  • Dec 5CMCUpdateAnalyst$78.00
  • Oct 24CMCUpdateMorgan Stanley$68.00
  • Oct 22CMCUpdateJefferies$70.00

Related

  • SEC14h
    SEC Form DEFA14A filed by Nkarta Inc.
  • SEC14h
    SEC Form DEF 14A filed by Nkarta Inc.
  • INSIDER7d
    SEC Form 4 filed by Arriola Dennis V
  • INSIDER7d
    SEC Form 4 filed by Wetherbee Robert S
  • INSIDER7d
    SEC Form 4 filed by Mcpherson John R
  • INSIDER7d
    SEC Form 4 filed by Hickton Dawne S
  • INSIDER7d
    SEC Form 4 filed by Perkins Tandra C
  • PR8d
    Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022